Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: Adjusted indirect meta-analysis

Haematologica

Volumn 95, Issue 2, 2010, Pages 340-342

  Kumar, Ambuj ^a,b   List, Alan F ^a,b   Hozo, Iztok ^c   Komrokji, Rami ^a,b   Djulbegovic, Benjamin ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c INDIANA UNIVERSITY NORTHWEST   (United States)

Author keywords

5 azacitidine; Decitabine; Hypomethylating agents; Myelodysplastic syndrome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; META ANALYSIS; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; SYSTEMATIC REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HUMANS; MYELODYSPLASTIC SYNDROMES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 76549103505     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.017764     Document Type: Letter

References (10)

1. Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - systematic review and meta-analysis. Haematologica. 2010;95(1)343-2.
2. Kumar A, List AF, Mhaskar R, Djulbegovic B. Efficacy of Hypo-Methylating Agents in the Treatment of Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ASH Annual Meeting Abstracts. 2008 November 16, 2008;112(11):3632.
3. Kumar A, List AF, Mhaskar R, Djulbegovic B, editors. Efficacy of Hypo-Methylating Agents in the Treatment of Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 14th Congress of the European Society of Hematology; 2008 June 4th to 7th; Berlin.
4. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006 Apr 15;106(8):1794-803.
5. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med. 1998;17(24):2815-34.
6. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15;20(10):2429-40.
7. WijerMans P, Suciu S, Baila L, Platzbecker U, Giagounidis A, Selleslag D, et al. Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups. ASH Annual Meeting Abstracts. 2008 November 16, 2008;112(11):226.
8. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of clinical epidemiology. 1997;50(6):683-91.
9. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. Indirect comparisons of competing interventions. Health technology assessment (Winchester, England). 2005;9(26):1-134, iii-iv.
10. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in medicine. 2002;21(16):2313-24.